Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and basal insulin analogs are essential antihyperglycemic therapies for many patients with type 2 diabetes mellitus (T2DM) (eg, those in need of large glucose-lowering effects or, based on recent updates to the official indications for 2 of the GLP-1 RAs). This Engaging the Patient activity will discuss newer insulin therapies as well as GLP-1 injectable therapies, including rationales and clinical trial evidence for combining these two agents. The activity includes a demonstration of clinician and patient interactions-ways to educate patients on the use of injectable medications, as well as approaches to reducing hypoglycemia and improving patient adherence.
In this Expert Perspective, Dr. Vanita Aroda answers important questions about the benefits and use of ultra-long-acting insulins as well as ways to overcome the therapeutic inertia associated with initiating and intensifying insulin therapy.
In this case presentation, Dr. Mathioudakis shares strategies for treatment intensification while minimizing the risk of hypoglycemia and highlights the differences between conventional and newer basal insulin products. He also describes how to appropriately initiate and dose newer basal insulin products in patients with type 2 diabetes.
Through real-time interaction with faculty, learners will evaluate the differences between conventional and newer basal insulins and review the clinical impact of hypoglycemia, as well as the strategies for detecting, preventing, and managing hypoglycemia.